Clinical and genetic assessment of the real cardiovascular risk It reclassifies to a higher risk category 7% of the low-risk patients, 15% of the moderate-risk patients and 23% of the high-risk patients. This signifies that for 1 of every 4 patients with high cardiovascular risk and for 1 in every 6 of those with moderate risk, according to the usual risk functions, in reality it is necessary to apply stricter therapeutic objectives.


Obstetrics & Gynecology

The new generation of Non-Invasive Prenatal Testing (NIPT) it analyzes the cell free fetal DNA in the mother’s blood to detect chromosomal abnormalities in the fetus.
Preeclampsia (PE)
Is defined as the onset, after week 20 of the pregnancy, of: 
- Proteinuria (presence of proteins in urine) 
The test benefits from incorporating the placental growth factor PlGF along with other ultrasound and biochemical factors to provide early detection of PE with high sensitivity.


Analysis of food intolerance, It is a test which allows the measure of levels on Specific Immunoglobuline G against more than 200 different food


  1. Circulogene
    Liquid biopsy tumor DNA sequencing, it utilizes NGS to monitor known tumor mutations in 50 established cancer- associated genes and further provides information on current FDA-approved treatment options.
  2.  Liquid Biopsy single gene
    Blood Test for (EGFR, KRAS, BRAF)
    The liquid biopsy
  3. NGS Cancer
    Is genetic panel that includes a full analysis of 94 genes associated with a predisposition to cancer, including common and unusual types.